IVIVA Medical Inc

IVIVA Medical Inc is a pioneering company with the slogan "Developing living therapeutics to cure chronic disease." Since its foundation in 2013, the company has been committed to revolutionizing the treatment of end-stage kidney disease (ESKD), which affects over 500,000 patients in the United States. IVIVA's approach focuses on developing living therapeutics to cure patients with kidney failure. Despite transplant being the only definitive treatment for ESKD, the majority of patients will never receive a donor kidney. To address this critical issue, IVIVA leverages emerging complimentary technologies in tissue engineering, 3D additive manufacturing, and stem cell biology. The company's mission revolves around using regenerative medicine to end the shortage of donor organs. IVIVA is at the forefront of developing biomimetic platforms and systems, not only to provide therapies but also to serve as the foundational building blocks for the next generation of advanced organ therapeutics. The significance of IVIVA's work is underscored by its recent Seed Round investment at 05 March 2021, which saw participation from Thynk Capital, LLC. and Bioverge. IVIVA Medical Inc's groundbreaking work in the area of regenerative medicine has the potential to reshape the landscape of chronic disease treatment. With its innovative approach and strong investor backing, IVIVA is poised to make a lasting impact in the fight against end-stage kidney disease.